寻求医学辅助生殖的女性不孕症患者发生多发性硬化的风险并未增加
基于丹麦注册数据的队列研究纳入310357名女性,分析女性不孕症与多发性硬化(MS)患病及发病的关联。女性不孕症患者发生MS的风险与明显生育力正常的女性相比未增加;接受医学辅助生殖(MAR)的女性MS患病率略高于未接受MAR而生育的女性,但该差异与不孕原因(男性因素与女性因素)无关。
要点
- 有女性不孕症记录的女性发生MS的风险与明显生育力正常的女性相比未增加。
- 接受MAR治疗女性的MS粗患病率为每1000人3.2,生育力正常对照为每1000人2.3。
- 首次MAR治疗时MS患病率的调整比值比为1.27(95%CI 1.07-1.52),但该差异与不孕原因无关。
核心结论
- 有女性不孕症记录的女性与明显生育力正常的女性相比,发生MS的风险未增加。
- 接受MAR的女性MS患病率略高于未接受MAR而生育的女性,但该差异与不孕原因(男性因素与女性因素)无关。
研究设计与样本
- 基于注册资料的队列研究,纳入1996年至2018年共310357名女性。
- 患病率分析采用横断面设计,发病率分析采用队列设计,随访时间长达24年。
- 纳入三个队列:55404名在丹麦IVF注册库中登记有女性不孕症诊断的女性;25096名仅记录男性因素不孕因而无女性不孕症诊断的女性;229857名年龄和日历匹配、在丹麦医学出生注册库(DMBR)中有首次生育记录且从未在IVF注册库中登记的女性。
- 采用对数二项回归比较患病率,采用Cox比例风险回归比较发病率。
主要发现
- 接受MAR治疗女性(无论不孕原因)的MS粗患病率为每1000人3.2,生育力正常的DMBR对照为每1000人2.3。
- 经年龄、日历和教育水平调整后,不孕女性首次MAR治疗时MS诊断的患病率比为1.27(95%CI 1.07-1.52),对照为生育力正常的DMBR女性。
- 与同样接受MAR治疗、男性伴侣有不孕症的女性相比,患病率比为1.00(95%CI 0.77-1.31)。
- 与任一生育力正常对照组相比,女性不孕症与MS发病之间未发现关联。
临床怎么用
- 作者认为,MS女性接受MAR治疗可能比无MS女性更频繁,原因包括对MAR治疗可能性了解更多、MS相关的性功能障碍,以及为避免在没有疾病修饰治疗(尤其高效治疗)的情况下度过不必要长时间而希望快速怀孕。
- 作者指出这些发现对处理育龄期MS女性的临床医生很重要。
局限性
- 不孕女性队列基于其选择接受生育治疗而高度选择,因此不包括未确诊不孕或出于某种原因选择不接受MAR治疗的女性。
- 由于观察性研究设计的性质,不能排除未测量和/或残余混杂的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is female infertility among women seeking medically assisted reproduction (MAR) associated with prevalent as well as incident multiple sclerosis (MS)? SUMMARY ANSWER: Women with a record of female infertility did not have an increased risk of developing MS compared with apparent fertile women; however, the prevalence of MS was slightly higher among women undergoing MAR compared with women who had a child without MAR, but this was not related to origin of infertility (i.e. male versus female factor infertility). WHAT IS KNOWN ALREADY: Women with MS have fewer children compared with women without MS. Persons with MS more often have other coexisting autoimmune disorders including hypothyroidism compared with the general population. Thyroid dysfunction is associated with ovarian cause of infertility, miscarriage and ovarian failure. Conversely, women with endometriosis, that is highly associated with infertility, also more often have other coexisting autoimmune diseases including MS and hypothyroidism compared with the general population. However, whether the low fertility rate among women with MS is due to a genetically predisposition to other autoimmune and endocrine disorders that leads to reduced fertility, or an active choice of the woman, disease-related pathology or treatment-specific effect on endocrine and/or ovarian function, is not completely understood. STUDY DESIGN, SIZE, DURATION: A register-based cohort study of a total of 310 357 women from 1996 to 2018. A cross-sectional design was used for analysing prevalence of MS, whereas a cohort design with up to 24 years of follow-up was used for analysing incidence of MS. PARTICIPANTS/MATERIALS, SETTING, METHODS: Three cohorts were included in the study (i) 55 404 women with a female infertility diagnosis registered in the Danish IVF register; (ii) 25 096 women with only male factor infertility recorded in the IVF register and thus no female infertility diagnosis and (iii) 229 857 age- and calendar-matched women with a record of first child birth in the Danish Medical Birth Register (DMBR) and no record ever in the IVF register. The prevalence and incidence of MS in the female infertility cohort were compared with the two control cohorts of apparent fertile women using log-binomial regression and Cox proportional hazard regression, respectively. MAIN RESULTS AND THE ROLE OF CHANCE: The crude prevalence of having MS per 1000 persons was 3.2 for women who had undergone MAR treatment regardless of origin of infertility (i.e. male versus female factor infertility) and 2.3 for fertile DMBR controls. The age, calendar and educational level adjusted prevalence ratio of having a diagnosis of MS at the first MAR treatment was 1.27 (95% CI 1.07-1.52) for infertile women compared with fertile DMBR controls, and 1.00 (95% CI 0.77-1.31) for comparison to women with a male partner with infertility who had also undergone MAR treatment. We found no association between incident MS and female infertility compared with either of the control groups of fertile women. LIMITATIONS, REASON FOR CAUTION: The cohort of infertile women is highly selected on the basis of their choice of having fertility treatment and thus does not include women with unestablished infertility or women who, for some reason, have chosen not to have MAR treatment. Additionally, due to the nature of the observational study design, we cannot exclude the possibility of unmeasured and/or residual confounding. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest that women with MS may undergo MAR treatment more often than women without MS due to more awareness about the possibility of MAR treatments, sexual dysfunction related to MS disease, but also need for timing of the pregnancy to avoid an unnecessary long time period without disease modifying therapy-especially of high efficacy-and hence a wish to conceive quickly. These findings are important for clinicians dealing with women with MS of childbearing age. STUDY FUNDING/COMPETING INTEREST(S): The authors received no financial support for the study. T.I.K. has served on a scientific advisory board for Novartis and has received support for congress participation from Biogen. M.M. has served on scientific advisory boards for Biogen, Sanofi, Roche, Novartis, Merck, Abbvie and Alexion. She has received honoraria for lecturing from Biogen, Merck, Novartis, Sanofi and Genzyme and has received research support and support for congress participation from Biogen, Genzyme, Roche, Merck and Novartis. The remaining authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Kopp TI, Pinborg A, Glazer CH, et al. Women with female infertility seeking medically assisted reproduction are not at increased risk of developing multiple sclerosis. Hum Reprod. 2022. PMID: 35265993. doi:10.1093/humrep/deac041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。